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Purpose/Objective: Meningiomas comprise one third of the the 
primary brain tumor cases and occupy the second place (up to 20%) 
after gliomas concerning the extension among the tumors of the CNS. 
Surgical resection is regarded as choice method for meningioma 
treatment. However, in cases of complex localization and in case of 
placement near vital neurovascular structures, and also in case of 
partial resection or extended tumor growth, usage of stereotactic 
radiosurgery allows preventing of possible complications and reaching 
of radiosurgical control over the tumor. 
Materials and Methods: 63 patients with meningiomas underwent 
treatment at MC'Cyber Clinic of Spizhenko'. Acquired results of 42 
patients were analyzed. Among them 21 patient previously underwent 
surgery (1-3 operations), and 24 patients did not previously undergo 
surgery. Tumor volume was defined between 1.6 ml to 86.6 ml (on 
average 26.8ml). All the patients underwent course of stereotactic 
radiosurgery with the use of CyberKnife system for 1-5 fractions (on 
average 4.45) depending on the tumor volume. Radiation dose ranged 
from 1500 to 2800 cGy. All patients underwent standard assessments, 
as CT, MRI, and also magnetic-resonance imaging in regime of 
diffusion-weighed images (DWI) with definition of actual diffusion 
coefficient – ADC (Apparent Diffusion Coefficient). DWI and ADC 
implementation before and after radiosurgical treatment allowed not 
only qualitative, but also quantitative interpretation conducting of 
acquired results and objective assessment of tumor tissue reaction 
onto the radiation exposure  
Results: Radiological results assessment of radiosurgical treatment 
was conducted in 3, 6, 12 months. In majority of the cases there was 
clinical response evidenced. For the time of patients’ observation for 
3-30 months (on average 17.36 months) tumor volume decreased in 25 
patients (56.2%), 16 patients (35.6%) had the tumor unchanged 
(stabilization) and 1 patient (2.2%) had tumor growth. ADC coefficient 
increase was determined in all patients with tumor volume decrease 
and also in some patients with stable mass lesions’ sizes, and it 
significantly decreased in those patients who had extended 
meningioma growth. Thus, diffusion coefficient increase is evidenced 
in 27 (64.3%) of the patients. Hereinafter the conditions of those 
patients continued improving. At the same time, according to the 
literature data, without taking into account the ADC of MRI diffusion-
weighed images, decrease of tumor (meningioma) after radiosurgery 
was observed only in 18%, and stabilization of the process was seen in 
74% of the patients. ADC diffusion parameters in our patients with 
meningiomas before the start of treatment comprised 0.6-0.96 
mm2/s. After radiosurgical treatment diffusion coefficient equaled 
0.64-1.64 mm2/s. 
Conclusions: Stereotactic radiosurgery with the use of CyberKnife is 
effective treatment method for brain meningiomas. Objective 
assessment of treatment results is possible only by means of standard 
radiological methods (CT, MRI), supplemented with special MRI modes 
(DWI) and ADC determination. 
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Purpose/Objective: Radiation necrosis (RN) of the brain is an 
important problem for the patient with malignant astrocytoma, 
especially treated with high-dose RT. Individualized radiation dose 
delivery according to radiosensitivity may reduce the incidence of RN 
while keeping enough anti-tumor effect. And anti-tumor effect of 
irradiation was closely related to anti-tumor immune response of the 
host. The purpose of this study is to evaluate whether some 
parameters, which speculate the host's immune strength, could 
predicted the occurrence of RN at initial treatment. 
Materials and Methods: Between 2006 and 2010, 64 patients with 
malignant astrocytoma were enrolled. All patients were treated with 
RT and concurrent temozolomide (TMZ) followed by adjuvant TMZ. 
Thirty-three patients received conventional RT and the other 31 
received hypofractionated high-dose IMRT. In the IMRT group, three-
layered PTVs were contoured (PTV-1: enhanced lesion with 5mm 
margin, PTV-2: 15mm surrounding the PTV-1, PTV-3: FLAIR-high area) 
and different doses (68Gy for PTV-1, 40Gy for PTV2 and 32Gy for PTV-
3) were delivered by 8 fractions. To estimate the immune strength of 
the patients, we used tumor-infiltrating lymphocytes (CD4+ helper T 
cells, CD8+ cytotoxic Tcells and FoxP3+ regulatory T cells (Treg) which 
suppresses the cytotoxic effect of CD8+ T cells) at first surgery, 
cerebrospinal fluid cells and proteins a week after first surgery. After 
treatment, MRI was performed with an interval of one or two months. 
We estimated the prognostic effect of these immunobiological 
parameters on overall survival (OS), progression-free survival(PFS) and 
RN-free survival (RNFS). 
Results: High-dose hypofractionated IMRT induced RN more frequently 
than conventional RT (relative risk (RR) 3.44, p=0.0067) and tumor-
infiltrating CD8+ T cells was also independent risk factor of RN (RR 
3.10,p=0.0262). On the other hand, the infiltration of FoxP3+ Treg 
indicated lower risk of RN but not statistically significant. One-year 
RNFS for CD8 infiltration without FoxP3 and FoxP3 infiltration without 
CD8 were 50% and100%. Two-year RNFS were 0% and 86%, respectively 
(p=0.0013).Tumor-infiltrating lymphocytes was not related to OS and 
PFS in the entire analysis. In the subgroup analysis of IMRT, the 
infiltration of CD8+ cells was higher risk factor of RN (RR 3.88, 
p=0.0041). In the conventional RT group, the infiltration of CD8+ 
Tcells was not the risk factor of RN but correlated with prolonged PFS 
(RR 0.21,p=0.0185). 
 
 
Conclusions: Tumor-infiltrating CD8+ T cells was the prognostic factor 
of RN after RT, especially high-dose RT, but was not related to OS. 
The analysis of tumor-infiltrating lymphocytes might be useful to 
prevent the occurrence of RN. 
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Purpose/Objective: To analyze the treatment outcomes and 
prognostic factors in patients with brain metastases (BM) from 
undiagnosed primary cancer (BM-UDP). 
Materials and Methods: Between January 2010 and October 2012, 
patients with brain metastases referred for palliative radiotherapy 
were enrolled for this study. BM-UDP patients underwent complete 
systemic survey for the origin of the cancer before the treatment 
began. All patients were treated with long-term palliative intent 
including whole brain radiotherapy (WBRT) and systemic therapies 
tailored for their primary origin. Patients were followed up until their 
death and overall survival (OS) were calculated from the day of BM 
diagnosis. Another group of patients with BM from diagnosed primary 
(BM-DP) who were treated in the same period of time were used for 
survival comparison. Potential prognosticators for OS in BM-UDP were 
analyzed. 
Results: Total 79 BM patients were treated and enrolled during this 
period, 37 were BM-UDP and 42 were BM-DP. There were no survival 
difference between BM-UDP and BM-DP patients compared by 
univariate analysis (p = 0.298). In BM-UDP patients, the median age 
was 61 years-old, 22 were male and 15 were female. The most 
common primary site was the lung (30/37). Median OS for these 
patients were 8.03 months. Multivariate analysis revealed that age, 
gender, extracranial metastases, number of BM lesions, and volume of 
the largest BM lesion were not prognosticators for OS. The only 
significant prognostic factor was performance status before WBRT. 
The median OS were 10.00 months and 2.89 months for patients with 
Karnofsky performance status (KPS) ≥ 70 and KPS < 70, respectively. 
(p = 0.006) 
